The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Golovina V.I.

Pirogov Russian National Research Medical University

Efremova O.I.

Pirogov Russian National Research Medical University

Zolotukhin I.A.

Pirogov Russian National Research Medical University

Treatment and Secondary Prevention of Venous Thromboembolic Events in Fragile Patients in a Real-life Practice

Authors:

Golovina V.I., Efremova O.I., Zolotukhin I.A.

More about the authors

Journal: Journal of Venous Disorders. 2021;15(2): 95‑102

DOI: 10.17116/flebo20211502195

Read: 1496 times

Download PDF (RU)
Contact the author
Table of contents

TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN FRAGILE PATIENTS IN A REAL-LIFE PRACTICE
TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN FRAGILE PATIENTS IN A REAL-LIFE PRACTICE

To cite this article:

Golovina VI, Efremova OI, Zolotukhin IA. Treatment and Secondary Prevention of Venous Thromboembolic Events in Fragile Patients in a Real-life Practice. Journal of Venous Disorders. 2021;15(2):95‑102. (In Russ.)
https://doi.org/10.17116/flebo20211502195

Подписка 2026 Флебология (Journal of Venous Disorders)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Fibrin mono­mer in diagnosis of cardiovascular diseases. Russian Cardiology Bulletin. 2024;(4-2):113-120
Asplenia — a new cause of thro­mbosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76
Fatal non-thrombotic pulmonary embo­lism in penis enla­rgement with inje­ctions of hyaluronic acid-based drugs. Fore­nsic Medi­cal Expe­rtise. 2025;(1):59-62
Signs of high embo­lic risk in iliocaval floating thro­mbi. Piro­gov Russian Journal of Surgery. 2025;(3):56-62
Asso­ciations between the gut microbiota-derived meta­bolites with the para­meters of 24-hour ambu­latory blood pressure moni­toring in patients on maintenance hemo­dialysis. Russian Journal of Preventive Medi­cine. 2025;(3):96-102
Current approaches to the prevention and treatment of post-thrombotic syndrome. Russian Journal of Preventive Medi­cine. 2025;(5):111-116
Difficulties in differential diagnosis of pulmonary dissemination. Journal of Respiratory Medi­cine. 2025;(2):79-82
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Hemo­stasis diso­rders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(3):39-44
Rela­tionship between gene­tic variants of coagulation system genes with venous thro­mbosis in women during pregnancy. Labo­ratory Service. 2025;(2):19-23
Abstract:

The review is devoted to direct oral anticoagulants (DOACs) in the treatment of venous thromboembolism (VTE) in fragile patients. This cohort includes elderly people (≥75 years old) and/or individuals with low body weight (≤50 kg) and/or impaired renal function (CrCl ≤50 mL/min). The authors analyze data from the RIETE, XALIA, PREFER-VTE and Dresden registers, as well as other studies considering anticoagulation in these patients. Risk of hemorrhagic complications is significantly higher in fragile patients receiving anticoagulation for VTE compared to the risk of VTE recurrence. In addition, a comparative analysis of DOACs with standard anticoagulation showed some advantages including lower incidence of major bleeding and VTE recurrence. These data can be valuable to determine the most rational approach for VTE in fragile patients.

Keywords:

direct oral anticoagulants
venous thromboembolism
pulmonary embolism
venous thrombosis
elderly age
fragile patient
low body weight
chronic kidney disease

Authors:

Golovina V.I.

Pirogov Russian National Research Medical University

Efremova O.I.

Pirogov Russian National Research Medical University

Zolotukhin I.A.

Pirogov Russian National Research Medical University

Received:

03.03.2021

Accepted:

23.03.2021

Close metadata

References:

  1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585-593.  https://doi.org/10.1001/archinte.158.6.585
  2. Oger E. Incidence of venous thromboembolism: a community-based Study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83(5):657-660. 
  3. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279(6):458-462.  https://doi.org/10.1001/jama.279.6.458
  4. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.  https://doi.org/10.1016/0140-6736(92)91054-C
  5. The Columbus Investigators: Buller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337(10):657-662.  https://doi.org/10.1056/NEJM199709043371001
  6. EINSTEIN Investigators; Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21.  https://doi.org/10.1186/1477-9560-11-21
  7. EINSTEIN-PE Investigators; Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. https://doi.org/10.1056/NEJMoa1113572
  8. AMPLIFY investigators; Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.  https://doi.org/10.1056/NEJMoa1302507
  9. Hokusai VTE Investigators; Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415. https://doi.org/10.1056/NEJMoa1306638
  10. RE-COVER II Trial Investigators; Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-772.  https://doi.org/10.1161/CIRCULATIONAHA.113.004450
  11. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-CS. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352. https://doi.org/10.1056/NEJMoa0906598
  12. Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, Schüler E, Schellong S, Kakkar A. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Thromb Haemost. 2017;117(11):2045-2052. https://doi.org/10.1160/TH17-03-0176
  13. Buchner DM, Wagner EH. Preventing frail health. Clin Geriatr Med. 1992; 8(1):1-17. 
  14. RIETE Investigators; Trujillo-Santos J, Beroiz P, Moustafa F, Alonso A, Morejon E, Lopez-Reyes R, Casado I, Porras JA, Flores K, Lopez-Nunez JJ, Monreal M. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res. 2020;193:160-165.  https://doi.org/https://doi.org/10.1016/j.thromres.2020.06.03510.1016/j.thromres.2020.06.035
  15. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-495.  https://doi.org/10.1503/cmaj.050051
  16. Robinson TN, Wu DS, Pointer L, Dunn CL, Cleveland JC, Moss M. Simple frailty score predicts postoperative complications across surgical specialties. Am J Surg. 2013;206(4):544-550.  https://doi.org/10.1016/j.amjsurg.2013.03.012
  17. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38(2):156-162.  https://doi.org/10.1093/ageing/afn293
  18. Muriel A, Jimenez D, Aujesky D, Bertoletti L, Decousus H, Laporte S, Mismetti P, Muñoz FJ, Yusen R, Monreal M; RIETE Investigators. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014;63(16):1675-1683. https://doi.org/10.1016/j.jacc.2014.01.058
  19. Tzoran I, Brenner B, Papadakis M, Di Micco P, Monreal M. VTE Registry: What Can Be Learned from RIETE? Rambam Maimonides Med J. 2014:29;5(4):e0037. https://doi.org/10.5041/RMMJ.10171
  20. Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators; Muñoz-Torrero JF, Bounameaux H, Pedrajas JM, Lorenzo A, Rubio S, Kearon C, Hernández L, Monreal M. Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. J Vasc Surg. 2011;54(6):26-32.  https://doi.org/10.1016/j.jvs.2011.05.114
  21. RIETE Investigators; Jimenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M. Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. J Am Coll Cardiol. 2016;67(2):162-170.  https://doi.org/10.1016/j.jacc.2015.10.060
  22. RIETE Investigators; Moustafa F, Giorgi Pierfranceschi M, Di Micco P, Bucherini E, Lorenzo A, Villalobos A, Nieto JA, Valero B, Samperiz AL, Monreal M. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. Res Pract Thromb Haemost. 2017;1(2):172-179.  https://doi.org/10.1002/rth2.12036
  23. RIETE Investigators; Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, Monreal M. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(1):26-31.  https://doi.org/10.1160/TH08-03-0193
  24. Riete Investigators; Nieto JA, Solano R, Ruiz-Ribó MD, Ruiz-Gimenez N, Prandoni P, Kearon C, Monreal M. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2010;8(6):1216-1222. https://doi.org/10.1111/j.1538-7836.2010.03852.x
  25. Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: Efficacy and safety of non-VKA oral anticoagulants. Thromb J. 2014;12:21.  https://doi.org/10.1186/1477-9560-12-21
  26. Ozturk M, Ipekci A, Kiyak SK, Akdeniz YS, Aydin Y, Ikizceli I, Sogut O. Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department. J Clin Med Res. 2019;11(2):106-113.  https://doi.org/https://doi.org/10.14740/jocmr366910.14740/jocmr3669
  27. Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc (Bayl Univ Med Cent). 2001;14(3):305-306.  https://doi.org/10.1080/08998280.2001.11927781
  28. Lopez-Nunez JJ, Perez-Andrés R, Di Micco P, Schellong S, Gomez-Cuervo C, Sahuquillo JC, Ciammaichella M, Morales MDV, Bosevski M, Monreal M; and the RIETE Investigators. Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism. TH Open. 2019;3(1):67-76.  https://doi.org/10.1055/s-0039-1683970
  29. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016;3(1):12-21.  https://doi.org/10.1016/S2352-3026(15)00257-4
  30. Keller L, Marten S, Hecker J, Sahin K, Tittl L, Beyer-Westendorf J. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry. Int J Cardiol. 2018;257:276-282.  https://doi.org/10.1016/j.ijcard.2017.10.097
  31. Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017;157:181-188.  https://doi.org/10.1016/j.thromres.2017.07.029
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.